MedTrace Logo

Naltrexone in Borderline Personality Disorder

NCT00124839 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-04-15

No results posted yet for this study

Summary

The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

Naltrexone

Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone

Sponsors & Collaborators

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • Martin Bohus, M.D. · University of Heidelberg, Central Institute of Mental Health Mannheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-10-31
Completion
2008-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00124839 on ClinicalTrials.gov